Lessons

    1. How do you determine diagnostic and treatment strategies for bladder tumors?

    2. How are advancements in MRI and office biopsies influencing bladder cancer treatment and staging?

    3. What are the key considerations for tumor resection in frail patients, including tissue sampling?

    4. How are bladder perforations managed differently in muscle invasive versus NIMBC?

    5. What are preferred treatment approaches for NIMBC including chemotherapy and immunotherapy?

    6. What are the approaches and challenges in managing various histological subtypes of tumors?

    7. What are the challenges in treating plasmacytoid variants with chemotherapy and radiation?

    8. How do specialists counsel bladder cancer patients on choosing between cystectomy and trimodal therapy?

    9. Describe techniques for performing cystectomy procedures

    10. Challenges and considerations in treating progressive muscle invasive bladder cancer

    11. Centralized care and organ-sparing surgeries in bladder cancer

    12. What are the key considerations for different urinary diversion methods, including neobladders?

    13. What are the best practices in stoma creation to prevent parastomal hernias?

    1. How should high-grade non-invasive bladder cancer be managed after initial BCG therapy?

    2. How is BCG intolerance identified and managed in non-muscle invasive bladder cancer?

    3. How do you estimate BCG success rates for various high-grade bladder cancer stages and conditions?

    4. How do BCG shortages impact bladder cancer treatment regimens?

    5. How do we handle varying patient responses to BCG and explore alternative treatments and trials?

    6. How are patients with carcinoma in situ (CIS) managed after induction BCG treatment?

    7. Managing T1 High-Grade Bladder Cancer Recurrence Post-BCG Induction

    8. What factors influence deciding cystectomy or bladder preservation in T1 high-grade bladder cancer?

    9. What are the alternative treatments for high-grade T1 bladder cancer patients unable to undergo cystectomy?

    10. How is bladder cancer managed after BCG therapy, including the use of blue light cystoscopy?

    11. What are the benefits and challenges of using pembrolizumab as an FDA-approved treatment?

    1. What are the considerations for using neoadjuvant chemotherapy in muscle invasive bladder cancer?

    2. What are the benefits of administering MVAC chemotherapy for bladder cancer patients?

    3. How do you decide between surgery and perioperative therapies for bladder cancer?

    4. When should oncologists discuss chemotherapy with patients post surgery?

    5. How do different bladder cancer variants respond to chemotherapy?

    6. How are high-risk patients counseled on chemotherapy and immunotherapy options?

    7. What are the implications of using cell-free DNA for predicting outcomes and guiding adjuvant therapy?

    8. What is the current approach to neoadjuvant chemotherapy cycles?

    9. What are the main considerations for recommending adjuvant radiation therapy in bladder cancer?

    10. How do findings from the POUT trial influence your approach?

    1. What is the importance of accurate staging and imaging in bladder cancer?

    2. How do you talk to patients about the risks of micrometastatic lymph node disease?

    3. How do you approach lymph node dissection in cancer treatment?

    4. How Does Radiation Oncology Fit into Trimodal Therapy and Bladder Preservation?

    5. How Do Patterns in Lymph Node Metastases Impact Surgical Approaches in Bladder Cancer?

    6. Can you tell us about your clinical trial on node dissection in bladder cancer surgery?

    7. What are the strict quality control measures and credentialing processes for this trial?

    8. What are the criteria for extended lymph node dissection in cystectomy patients?

    9. What is the importance of thorough surgical techniques and volume requirements in radical cystectomy procedures?

About this course

  • 43 lessons
  • 2.5 hours of video content